What approach is now AHA/ACC guideline-recommended for a patient with primary hypercholesterolemia, with an LDL-C of 192 mg/dL? Take Quiz #3.
Semaglutide Linked to Reduced Risk for MACE Months Before Weight Loss Begins: Post Hoc Analysis
Semaglutide was associated with a significant reduction in risk for major adverse cardiovascular events after just 3 months of treatment in a population with established CVD.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
Clinically Validated Blood Test Identifies Preeclampsia Risk Early in Pregnancy, New Study Shows
A simple RNA-based blood test can identify the risk of hypertensive disorders in pregnancy months before symptoms appear, researchers reported.
Primary Viewpoints Episode 4: Lp(a): The Next CVD Target?
Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.
High Blood Pressure Advisory in EHR Improves Hypertension Diagnosis, Control Across a Primary Care Network
An EHR advisory that combined alerts to medical assistants with escalation to clinicians increased likelihood of hypertension control by a mean 18% per month.
Oral Semaglutide Cuts MACE Risk by 14% in High-Risk Adults: Daily Dose
Your daily dose of the clinical news you may have missed.